US State Disparities in Colorectal Cancer Rates
the Cancer Therapy Advisor take:
Greater progress in reducing colorectal cancer (CRC) incidence and mortality rates was observed in Northeastern states compared to Southern states, according to an article published online in the journal Cancer.
In this study, the investigators aimed to quantify disparities in CRC rates between Louisiana (representing Southern states) and New Jersey (representing Northeastern states) if differences in risk factors, screening, and stage-specific CRC survival were eliminated.
The Microsimulation Screening Analysis Colon microsimulation model estimated age-adjusted CRC incidence and mortality rates in Louisiana (between 1995 and 2009) under four assumptions: that residents in both states had the same smoking and obesity prevalence; CRC screening rates; stage-specific CRC relative survival ; and that the previous three assumptions were true.
Results showed the CRC incidence rate in Louisiana decreased by 3.5% when it had the same risk factors as New Jersey, and by 15.2% when it had the same screening rate as New Jersey.
If Louisiana had New Jersey’s risk factors, screening, and survival rates, the CRC mortality rate would be reduced by 3.0%, 10.8%, and 17.4%, respectively.
The modeled rates per 100,000 individuals in Louisiana had a greater reduction than the rates observed in New Jersey for both CRC incidence and mortality rates (116.4 vs. 130.0 and 44.7 vs. 55.8, respectively).
The study suggests that the differences in poor outcomes between Southern states and Northern states could be reduced if Southern states could achieve the same levels of screening, survival, and risk factors as those of Northern states.
Greater progress in reducing colorectal cancer incidence, mortality rates observed in Northeastern states compared to Southern states.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer